Clinical trials: Enterovirus
Hepatitis A
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule
The aim of this study is to evaluate the long-term persistence of hepatitis A antibodies at 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 years after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A…
- Trial name
- NCT00289757
- Testing
- Havrix™
- Where
- Belgium
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Hepatitis A
Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults
This protocol posting describes the booster phase of the study. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00289731).
- Trial name
- NCT00603252
- Testing
- Twinrix, Engerix-B, Havrix
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Poliomyelitis Vaccines
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine
The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.
- Trial name
- NCT01021293
- Testing
- Poliorix™, Oral Poliovirus vaccine
- Where
- China
- Volunteers
- 1,101 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis A
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young…
- Trial name
- NCT00197015
- Testing
- Havrix®, M-M-R®II, VARIVAX®
- Where
- 42 sites in United States
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haemophilus Infections, Diphtheria
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.
- Conditions
- Haemophilus Infections, Diphtheria, Tetanus, Polio
- Trial name
- NCT00855855
- Testing
- DTaP-IPV/Hib
- Where
- 59 sites in United States
- Volunteers
- 20,830 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pertussis, Diphtheria
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTaP-IPV combined vaccines as a three-dose primary vaccination at 2, 4 and 6 months of age compared to commercially available…
- Conditions
- Pertussis, Diphtheria, Poliomyelitis, Tetanus
- Trial name
- NCT00319852
- Testing
- DTaP-IPV combined vaccine, DTaP vaccine
- Where
- South Korea
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Sanofi
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '2+1'sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822767
- Testing
- sIPV-sIPV-bOPV vaccination schedule, wIPV-wIPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Diphtheria, Tetanus
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00313911
- Testing
- DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib
- Where
- 2 sites in Mexico, Peru
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hand, Foot and Mouth Disease
A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
This study is a sero-survey study of infants aged 6 months to 71 months in Bandung City and West Bandung District. As initial data to find out how many children have been exposed to human enterovirus type 71 (HEV-71) which causes…
- Trial name
- NCT05637229
- Where
- 2 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Poliomyelitis, Tetanus
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Hepatitis B
- Trial name
- NCT00352963
- Testing
- Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec
- Where
- 22 sites in Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Viral; Infection, Coxsackie(Virus)
PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers
Phase 1, first-in-human, randomized, double-blind, placebo-controlled, multiple-dose-escalation study to evaluate the safety, tolerability and immunogenicity of PRV-101, a coxsackie virus B vaccine, in healthy volunteers.
- Trial name
- PROVENT (NCT04690426)
- Testing
- PRV-101
- Where
- Finland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Provention Bio, Inc.
Post-transplant Hepatitis C
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options.
- Trial name
- NCT01779518
- Testing
- Sofosbuvir, Ribavirin, Pegylated Interferon
- Sponsor
- Gilead Sciences
Hepatitis A
Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population
GlaxoSmithKline Korea has submitted a registration file for its hepatitis A vaccine. The present study will collect clinical data in the local target population as per the requirement of Korean Food and Drugs administration (FDA).
- Trial name
- NCT00237991
- Testing
- Hepatitis A
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hand-foot-mouth Disease, Infection; Viral, Enterovirus
Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children
A Phase I clinical trialto evaluate the safety of an Inactivated Enterovirus Type 71 Vaccine in healthy children (3-11y) and infants (6-35m).
- Trial name
- NCT01273246
- Testing
- 100U inactivated Enterovirus Type 71 Vaccine, 200U inactivated Enterovirus Type 71 Vaccine, 400U inactivated Enterovirus Type 71 Vaccine
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Poliomyelitis, Acellular Pertussis
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
The new formulation administered as a 4th consecutive dose will be compared to the current formulation of the vaccine in this partially double blind study.
- Conditions
- Poliomyelitis, Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00611559
- Testing
- Infanrix™ penta, Infanrix™ hexa
- Where
- 3 sites in Russia
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Enterovirus, Rhinovirus
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
- Trial name
- NCT03605862
- Testing
- Nitazoxanide
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 1,756 people
- Sponsor
- Romark Laboratories L.C.
Diphtheria, Tetanus
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
This study was designed to assess the lot comparability of DAPTACEL, as well as the safety and immunogenicity of DAPTACEL when co-administered with other recommended infant vaccines. Stage I Primary Objectives: 1.
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Polio
- Trial name
- NCT00662870
- Testing
- DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
- Where
- 26 sites in United States
- Volunteers
- 1,941 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hepatitis B, Acellular Pertussis
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine
This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month…
- Conditions
- Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b, Diphtheria
- Trial name
- NCT01457560
- Testing
- DTPa-HBV-IPV/Hib (Infanrix hexa™), OPV
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine among persons with prior vaccination with acellular vs whole-cell pertussis vaccine.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00304265
- Testing
- COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Where
- 17 sites in Germany
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes
- Trial name
- NCT07457060
- Testing
- 2wIPV+1sIPV, 1wIPV+2sIPV, 3wIPV
- Where
- 3 sites in Philippines
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd